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Abstract
The claimed beneficial effects of the Mediterranean diet include prevention of several age-related dysfunctions including
neurodegenerative diseases and Alzheimer-like pathology. These effects have been related to the protection against
cognitive decline associated with aging and disease by a number of polyphenols found in red wine and extra virgin olive oil.
The double transgenic TgCRND8 mice (overexpressing the Swedish and Indiana mutations in the human amyloid precursor
protein), aged 1.5 and 4, and age-matched wild type control mice were used to examine in vivo the effects of 8 weeks
dietary supplementation of oleuropein aglycone (50 mg/kg of diet), the main polyphenol found in extra virgin olive oil. We
report here that dietary supplementation of oleuropein aglycone strongly improves the cognitive performance of young/
middle-aged TgCRND8 mice, a model of amyloid-ß deposition, respect to age-matched littermates with un-supplemented
diet. Immunofluorescence analysis of cerebral tissue in oleuropein aglycone-fed transgenic mice showed remarkably
reduced ß-amyloid levels and plaque deposits, which appeared less compact and ‘‘fluffy’’; moreover, microglia migration to
the plaques for phagocytosis and a remarkable reduction of the astrocyte reaction were evident. Finally, oleuropein
aglycone-fed mice brain displayed an astonishingly intense autophagic reaction, as shown by the increase of autophagic
markers expression and of lysosomal activity. Data obtained with cultured cells confirmed the latter evidence, suggesting
mTOR regulation by oleuropein aglycone. Our results support, and provide mechanistic insights into, the beneficial effects
against Alzheimer-associated neurodegeneration of a polyphenol enriched in the extra virgin olive oil, a major component
of the Mediterranean diet.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
affecting a large proportion of aged people in the developed
countries, where it represents a severe burden for its dramatic
social impact and for national health budgets. The key histopath-
ological sign of AD is the presence, in several brain areas, of
intracellular neurofibrillary tangles of hyperphosphorylated tau, of
minute extracellular amyloid deposits found in diffuse and senile
plaques and around cerebral vessels and of dystrophic and
degenerating neurites [1,2]. Presently, functional alterations and
behavioral deficits that characterize AD are thought to result
primarily from the presence of plaque deposits [3], whose main
component is a polymeric fibrillar form of the 42 amino acid
peptide (Ab42) generated by proteolysis of the membrane amyloid
precursor protein (APP) [3]. Plaque load results from complex
equilibria between Ab deposition and clearance, where autophagy,
a lysosome-mediated catabolic pathway responsible for turnover of
long-lived proteins and organelles, appears to perform a key role
[4,5]. Autophagy protects neurons against Ab-induced cytotoxicity
suggesting its possible role in Ab clearance [6]; moreover, the
induction of autophagy by rapamycin in mouse models of AD
results in a decreased accumulation of Ab and aggregated tau [7].
More recently, the interest in deciphering the relation between
plaque burden, tissue functional impairment and neuronal death
has focused the importance, as the main toxic species to neurons,
of the oligomeric pre-fibrillar assemblies originating at the onset of
fibril growth [8–12]. Accordingly, the research of treatments able
to delay AD occurrence and to relieve its symptoms has shifted
from the development of molecules interfering with fibril growth to
that of molecules able to counteract the appearance of toxic
oligomeric intermediates.
Focusing dietary regimens associated with a reduced risk of AD
in the aged population can be useful to find molecules exploitable
for AD prevention and therapy. Mounting evidence supports the
beneficial effects of the Mediterranean diet (MD) in preventing
age-related dysfunctions, cancer, neurodegenerative diseases and
in attenuating AD-like pathology and cognitive deterioration [13–
18]. In particular, MD appears to be effective against mild
cognitive impairment and its conversion to AD [13]. Studies in
rodents suggest that diet supplementation with polyphenol-rich
components of the MD such as red wine and extra virgin olive oil
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(EVOO) improves learning and behavioral deficits associated with
aging and disease [19,20]. In addition, several reports, including
the ‘‘Three city study’’ [21] support a strict association between
many protective effects of the MD and the sustained assumption of
EVOO. In particular, a number of polyphenols and secoiridoids
found in EVOO, including oleocanthal, hydroxythyrosol and
oleuropein aglycone (OLE), have been considered potentially
responsible for the beneficial effect of MD [22–26]. Here we
describe a comprehensive study on OLE protection against AD in
the TgCRND8 (Tg) mouse model of Ab deposition. Our
behavioral, biochemical and histochemical data in OLE-fed
animals agree with the key role of amyloid plaques as the main
responsible of neuronal network impairment in brain [27]; they
also support the beneficial effects of dietary EVOO and highlight
the possibility that OLE intake may be useful to prevent AD or, at
least, to delay the appearance, and to reduce the severity, of its
symptoms.
Materials and Methods
Ethics Statement
Transgenic CRND8 mice encoding a double-mutant of
APP695 [28] and wild type (wt) control littermates were used
following the ECC (DL 116/92, Directive 86/609/EEC) and
National guidelines for animal care. The protocol was approved
by the Committee on the Ethics of Animal Experiments of the
Italian Ministry of Health (Permit Number: 283/2012-B).
Animals
The following 2 age groups of mice (equally divided for sex)
were used: 1.5 month-old wt (n = 16) and pre-plaque Tg (n= 16)
mice, 4 month-old wt (n = 16) and Tg (n= 16) mice. Different diet
treatments were equally given to each age group of wt and Tg
mice: 8 weeks with a 5.0% fat diet (10 g/day per mouse) either
alone (untreated) or containing OLE (50 mg/kg of diet) (OLE-
fed). We used a modified low-fat AIN-76A diet composed of
50.0% sucrose, 5.0% fat, 20.0% casein, 15.0% corn starch, 5.0%
powdered cellulose, 3.5% AIN-76 mineral mix, 1.0% AIN-76A
vitamin mix, 0.3% DL-methionine and 0.2% choline bitartrate
(Piccioni, Italy).
Oleuropein Deglycosylation
Oleuropein (Extrasynthase) deglycosilation was performed
according to Konno et al. [29] with minor modifications [23].
Briefly, a 10 mM solution of oleuropein in 0.1 M sodium
phosphate buffer, pH 7.0, was incubated with 28.7 I.U./mL of
b-glycosidase overnight at room temperature in the dark. The
reaction mixture was centrifuged at 10,0006g for 15 min to
precipitate the aglycone. The complete oleuropein deglycosylation
was confirmed by assaying the glucose released in the supernatant
with the Glucose (HK) Assay Kit (Sigma). GC-MS analysis showed
the absence of any oleuropein in the precipitate and the
substantially total recover of OLE in the same precipitate. A
100 mM OLE stock solution in DMSO was stored protected from
light and diluted in oil immediately before diet supplementation.
Behavioral Experiments
At the end of the diet treatment, 3.5 month-old and 6 month-
old OLE-fed and untreated Tg and wt mice were pooled
according to the treatment and genotype and behaviourally tested.
The apparatus and procedures used for the ‘‘Step-Down’’
inhibitory avoidance test were previously described [30]. The
apparatus was an open field plexiglas box (40640 cm) with a steel
rod floor and a plexiglas platform (46464 cm) set in the centre of
the grid floor to which intermittent electric shocks (20 mA, 50 Hz)
were delivered. On day 1 (training test, TT), each mouse was
placed on the platform and received an electric shock for 3 s when
it stepped down placing all paws on the grid floor. Responsiveness
to the punishment in the TT was assessed by animal vocalization;
only those mice that vocalized touching the grid (about 70% of
mice) were used for retention test (RT). 24 h after TT, each mouse
was placed on the platform again (RT). The latencies were
measured, considering 180 s as the upper cut-off, during TT and
RT. The tests were carried out between 10:00 A.M. and
1:00 P.M.
For object recognition test (ORT), we modified our previously
described method [31] using a white box (60650625 cm) with a
grid floor covered by white filter paper. A 75 Watt lamp was
suspended 50 cm above the box. Mouse behaviour was recorded
by a video-tracking/computer-digitizing system (HVS Image,
UK). The day before testing, the mice were allowed to explore the
box for 5 min. A session of two trials (T1 and T2) at 60 min
interval was given on the test day. In T1, the time spent by each
mouse exploring two identical 8.0 cm side grey cubes presented
for 10 min in two opposite corners of the box was recorded.
During T2, one of the cubes was replaced by a 8.0 cm side grey
cylinder, and the mice were left in the box for 5 min. The time
spent for the exploration of the familiar (F) and the new (N) object
were recorded and a discrimination score (D=N/N+F) was
calculated. A discrimination score above 0.5 indicates the ability of
mice to discriminate between the familiar and novel objects while
a score below or equal to 0.5, reflecting a novel object exploration
time less or equal to the half of the total time spent between the
two objects, indicates memory impairment in this task [32,33].
Animal Tissue Processing
After completing the behavioral tests, the mice were sacrificed
by cervical dislocation and the brains were rapidly removed and
divided sagittally. For protein analysis, cortical and hippocampal
samples from one hemibrain were immediately sectioned, snap-
frozen and stored at280uC. The other hemibrain was postfixed in
phosphate-buffered 4.0% paraformaldehyde, pH 7.4, at 4uC for
48 h, rinsed in PBS and paraffin embedded for immunohisto-
chemistry and Thioflavin S staining.
Cell Treatment
N2a murine neuroblastoma cells (ECACC) were plated in
MEM supplemented with non-essential amino acids, 10% FCS,
antibiotics and glutamine, cultured 24 h, treated with different
concentrations of OLE for increasing time periods and evaluated
for viability by the NR Uptake assay, as previously described [24].
The autophagy markers were determined by western blotting on
cell lysates.
Immunohistochemistry, Histochemistry and Western
Blotting
Histochemical and immunohistochemical analyses were per-
formed on 5.0 mm coronal paraffin-embedded sections, as
previously described [34]. The sections were incubated overnight
at 4uC with the primary antibodies (Abs) (Table 1) diluted in
0.1 M PBS, pH 7.4, with Triton X-100 (0.3%) and BSA (5.0 mg/
ml). For Ab plaque identification and astrocyte staining with
GFAP, tissue sections were incubated for 1.0 h with the
biotinylated secondary Ab (Vector Laboratories, USA) diluted
1:1000 in PBS 0.1 M/BSA (1.0 mg/ml); immunostaining was
visualized using the avidin-biotin system (Vectastain) and 3,39-
diaminobenzidine plus Nickel (DAB Kit) (Vector Laboratories,
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USA) as the chromogen. Fluorescent immunohistochemistry
experiments were as previously reported [35]. The sections were
incubated for 1.0 h with blocking solution (BS) containing 0.25%
Triton X-100, 5.0 g/l BSA and 5.0% normal goat serum for
polyclonal Abs or 5.0% normal horse serum for monoclonal Abs
in 0.1 M PBS, pH 7.4, and then overnight at 4uC with the
primary Ab (Table 1). On day 2, the sections were incubated for
1.0 h in the dark with the appropriate fluorescent secondary Ab
(Alexa Fluor 594- or 488-conjugated monoclonal anti-mouse and
polyclonal anti-rabbit Ab, Invitrogen, USA) diluted 1:400 in BS.
For double immunostaining, the sections were incubated with the
second primary Ab in the dark overnight at 4uC. On day 3, the
slices were incubated in the dark for 1.0 h at room temperature
with the second fluorescent Ab diluted 1:400 in BS. Analysis of
negative controls (not treated with the primary Ab) was
simultaneously performed to exclude the presence of non-specific
immunofluorescence staining, cross-immunostaining, or fluores-
cence bleed-through. Thioflavin S staining was as previously
described [35]. The rehydrated sections were incubated with
0.25% KMnO4 for 4.0 min, washed with water, incubated with a
0.1% NaBH4 solution for 5.0 min and placed in phosphate buffer
(411 mM NaCl, 8.1 mM KCl, 30 mM Na2HPO4, 5.2 mM
KH2PO4), pH 7.2 for 30 min at 4uC. The sections were washed,
incubated in 0.05% Thioflavin S (in 50% ethanol) for 8.0 min in
the dark, washed twice in 80% ethanol for 10 s and incubated in
phosphate buffer for 30 min at 4uC. The sections were cover
slipped using Vectashield mounting medium with or without
DAPI (Vector Laboratories, USA). Representative images were
acquired by an Olympus BX63 microscope coupled to CellSens
Dimension Imaging Software (Olympus, Italy). For western blotting
analysis, tissue samples were homogenized in ice-cold RIPA lysis
buffer, the cells were directly lysed in Laemmli sample buffer, and
40 mg of proteins were applied to SDS-PAGE (10% or 15%
acrylamide resolving gel) [36] for electrophoresis. The separated
proteins were transferred onto 0.45 mm nitrocellulose/PVDF
membrane (Hybond-C, Amersham Life Science) and incubated
overnight at 4uC with the primary Ab (see Table 1). The day after,
the blots were incubated for 1.0 h with the HRP-conjugated
secondary Ab (Biorad) diluted 1:7500 in BS. The immunocom-
plexes were visualized using enhanced chemiluminescence (ECL,
Pierce, USA) and acquired using ImageQuant 350 system (GE
Healthcare, UK). Band densitometric analysis was performed
using Image Quant TL software (GE Healthcare, UK). The bands
were normalized to b-actin or GAPDH level. All primary Ab
concentrations were titrated to provide optimal staining. The
groups of untreated or OLE-fed wt mice were pooled for western
blotting analyses.
Determination of Ab Plaque-load
To quantify Ab plaque burden, cortices and hippocampi of the
sections stained with an anti-Ab42 Ab were digitized and acquired
with an Olympus BX63 microscope equipped with CellSens
Dimension software (Olympus, Germany) as previously reported
[37]. 6 coronal brain sections, separated by 60 mm interval, from
each mouse (4–5 animals/group) were analyzed. Plaque number
and total area were determined automatically. Brain regions were
based on the mouse brain atlas [38].
ELISA
Soluble and insoluble Ab fractions were isolated from cortex
homogenates using a four step extraction protocol [39]. At each
step, sonication in an appropriate buffer was followed by
centrifugation at 100,0006g for 1 hr at 4uC. The supernatant
was then removed, and the pellet was sonicated in the next
solution used in the sequential extraction process. For four-step
extraction, sonication of the frozen tissue began in Tris-buffered
saline (TBS) (20 mM Tris and 137 mM NaCl, pH 7.6), which
contained protease inhibitors (protease inhibitor cocktail from
Sigma St. Louis USA). The next three sequential extraction steps
used 1% Triton X-100 in TBS with protease inhibitors, 2% SDS
in water with the same protease inhibitors, and 70% formic acid
(FA) in water. SDS-soluble fractions were loaded directly onto
ELISA plates, whereas FA-soluble fractions were diluted 1:20 in a
neutralization buffer (1 mol/L Tris base, 0.5 mol/L NaH2PO4)
before loading. Levels of Aß40 and Aß42 were analyzed using an
ELISA kit (Biosource, Camarillo, CA, USA) according to the
manufacturer’s instructions. The plates were read at 450 nm using
a plate reader (Molecular Dynamics, Sunnyvale, CA). All values
were calculated as pmol per g based on the wet weight of brain
cortical tissues.
Thiobarbituric Acid Reactive Substances (TBARS) Assay
The mouse cerebral cortex was homogenized in RIPA buffer
(10% w/v) containing the chelating agent diethylenetriamine
pentaacetic acid (500 mM); 0.2 mL of suspension were added to
4.0 mL of 36 mM TBA solubilised in 10% CH3COOH, pH 4.0
[40]. After heating for 60 min at 100uC, the reaction was stopped
by cooling the test tubes in ice for at least 2 h. 1.5 ml of n-butanol
was added and each test tube was vigorously mixed for 30 s and
centrifuged at 2506g for 10 min. The organic phase was
separated and sample absorbance at 532 nm was determined
spectrophotometrically. TBARS were quantified using 1,1,3,3-
tetramethoxypropane as a standard. Each sample was evaluated
twice.
Data Analysis
One-way ANOVA, followed by Bonferroni’s post-hoc test was
used to analyse Beclin 1, LC3, Cathepsin B, p62 and Aß40 and
Aß42 ELISA, TBARS levels, ORT and step down data. Unpaired
two tailed Student’s t-test was used to analyse Ab plaque burden.
Statistical analyses were carried out with OriginPro 8.1 and
statistical significance was defined as P,0.05. Data are reported as
mean values 6 standard error of the mean (S.E.M).
Results
OLE Improves Memory Deficits in TgCRND8 Mice
TgCRND8 mice are cognitively impaired since the age of 3
months [28,30] and, as already reported by us [34], no differences
are present between 3- and 7-month-old TgCRND8 mice.
Therefore, in both genotypes mice of 3.5 and 6 months of age
were grouped to increase the number of animals evaluated for
cognitive function after 8 weeks of administration of food
supplemented or not with OLE (n= 12/group for all groups).
OLE treatment was well tolerated and no treated animals died.
Memory performance was investigated by two widely used tests,
the step down inhibitory avoidance and the ORT. No significant
differences were observed between wt and OLE-fed or untreated
Tg mice during the TT of the step down test. However, in the
24 h RT step-down latencies recorded for Tg mice were
significantly reduced respect to wt mice and not significantly
different from training latency (P.0.05), indicating that Tg mice
were unable to memorize the punishment and to perform the
inhibitory avoidance. OLE administration to Tg mice significantly
improved their performance, that reached the level displayed by
wt mice (Fig. 1A). These findings did not result from any difference
in motility or exploratory activity, as evaluated in the rotarod and
hole board tests (data not shown) nor from different sensitivity to
Oleuropein Aglycone on AD-Like Pathology
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pain in the investigated mice. Then, the same mice were tested for
ORT with a retention interval of 60 min. In the T1 trial the
exploration time of the familiar object was comparable in the four
groups, where OLE-fed and untreated animals showed no
deficiencies in exploratory activity, directional movement towards
the objects and locomotor activity. In the T2 trial, untreated Tg
mice exhibited impairments in novel object preference compared
to wt mice, as shown by the significant reduction in the
discrimination score (untreated Tg: 0.376760.051; untreated wt:
0.590960.037), (Fig. 1B). The ability of OLE-fed Tg mice to
discriminate between the familiar and novel object was signifi-
cantly improved (0.6060.073) respect to that of untreated Tg mice
and undistinguishable from that of wt mice (OLE-fed:
0.652560.044; untreated: 0.590960.037). Altogether, the results
of the memory performance tests indicate that in our mouse model
cognitive impairment is completely prevented/rescued by OLE
administration to young/middle-aged Tg mice.
OLE Modifies Ab Burden in TgCRND8 Mice
Next, we checked whether the improved cognitive performance
of OLE-fed young/middle-aged Tg mice resulted from any altered
amyloid load respect to untreated Tg mice. Few, round-shaped,
small to medium size plaques were detected by an anti-Ab42 Ab in
the cortex and hippocampus of untreated 3.5-month-old Tg mice
(Fig. 2A). In 6-month-old Tg mice the Ab load became heavier
with a calculated total plaque area in the cortex and hippocampus
of about 1600 mm2 and 1400 mm2, respectively (Fig. 2A), which
was markedly reduced in the brains of age-matched Tg mice fed
with OLE (Fig. 2A). Quantitative analysis of total Ab plaque area
and number in the cortex and the hippocampus revealed that the
effect of OLE treatment was significant both in 3.5- and 6-month-
old Tg mice (Fig. 2B), supporting a remarkable protective effect of
OLE against early and middle stage of Ab deposition. Ab40 and
Aß42 SDS and FA soluble fractions measured in the cortex of
OLE-fed Tg mice of both ages were significantly reduced as
compared to those measured in age-matched untreated Tg mice
(Fig. 2C).
Thioflavin S and the OC Ab which specifically recognizes
fibrillar oligomers and amyloid fibrils [41], showed that in both the
cortex (Fig. 3) and hippocampus of OLE-fed Tg mice of both ages
the radiating plaques displayed a less dense core surrounded by
fewer and smaller round-shaped deposits than in untreated Tg
mice. Moreover, in the brain of 6-month-old Tg mice, displaying
an intermediate stage of plaque deposition, feeding with OLE
resulted in the presence of several radiating plaques with ribbon-
like/diffuse core and in a remarkable presence of fluffy deposits
(arrow in Fig. 3), whereas the plaques found in untreated Tg mice
typically displayed a very dense core (arrowhead in Fig. 3).
Altogether, these findings suggest that OLE, besides interfering
with de novo amyloid deposition, favours preformed plaque
disassembly.
OLE Induces Autophagy in the TgCRND8 Brain
It is widely recognised that autophagy protects neurons from
Ab-induced cytotoxicity, thus we investigated whether autophagy
was involved in the interference of OLE with the de novo
deposition and disassembly of Aß. Actually, an intense bright and
punctate immunoreactivity for Beclin 1, a protein involved in the
initiation and execution of autophagy, was detected in the soma,
perikarya and dendrites of neurons in different layers of
somatosensory/parietal (Fig. 4A) and entorhinal/piriform cortices
of Tg mice fed with OLE as compared to age-matched untreated
Tg mice with no apparent age-related differences. Although to a
lesser extent than in OLE-fed Tg mice, Beclin 1 immunoreactivity
was stronger also in OLE-fed wt mice than in untreated animals,
as exemplified for 3.5-month-old mice in Fig. 4A, suggesting a
general effect of OLE as inducer of Beclin 1 expression. In the
cortex of OLE-fed animals of both ages, Beclin 1 levels showed a
trend towards an increase in wt mice and a significant increase in
the Tg mice compared to the respective age-matched untreated
animals, as exemplified in Fig. 4B for mice of 3.5 months of age.
OLE-induced autophagy was further confirmed by immunohisto-
chemical analysis of LC3-II, the membrane-associated lipidated
LC3 form that appears in newly formed autophagosomes [42].
Stronger and brighter LC3 puncta were detected in the neuronal
cell bodies and processes in the somatosensory/parietal (Fig. 4C)
and entorhinal/piriform cortices of Tg mice fed with OLE, as
compared to age-matched untreated Tg mice. As for Beclin 1,
LC3 immunoreactivity was stronger also in all OLE-fed than in
untreated (Fig. 4C) wt mice. As for Beclin 1, in the cortex of OLE-
Table 1. Antibodies employed in the study.
Antibody Specific Dilution Host Source
WB IHC
Ab42 Ab peptide, aa 1–42 ND 1:200 Rabbit Millipore
Cathepsin B Procathepsin B and mature Cathepsin B 1:1000 1:100 Rabbit Millipore
SQSTM1/p62 SQSTM1/p62 protein 1:1000 1:200 Mouse abcam
Beclin 1 Beclin 1 protein 1:1000 1:200 Rabbit abcam
LC3 microtubule-associated protein light chain 3 1:1000 1:200 Rabbit Novus Biologicals
GFAP Glial fibrillary acidic protein ND 1:500 Rabbit Dako
Iba 1 Ionized calcium binding adaptor molecule 1 ND 1:250 Rabbit Wako
OC Amyloid fibrils and fibrillar oligomers ND 1:1000 Rabbit CG Glabe
P-p70S6K P-p70 S6 kinase (Thr389) 1:1000 ND Rabbit CST
p70S6K p70 S6 kinase 1:1000 ND Rabbit CST
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 1:1000 ND Rabbit Santa Cruz
b-Actin C-terminal b-actin fragment (C11) 1:5000 ND Rabbit Sigma-Aldrich
Legend: aa, amino acid; WB, western blot; IHC, immunohistochemistry, ND, not done.
doi:10.1371/journal.pone.0071702.t001
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fed Tg and wt mice of both ages LC3-II levels showed a trend
towards an increase in the wt mice and a significant increase in the
Tg mice respect to age-matched untreated wt and Tg mice, as
exemplified for 3.5-month-old mice (Fig. 4D). Overall, our data
indicate that OLE triggers autophagy not only in Tg but also in wt
mice suggesting a possible beneficial effect of this polyphenol also
against age-related neurodegeneration such as that occurring in
sporadic AD, with an effect similar, at the molecular level, to that
elicited by caloric restriction [43]. In general in the hippocampus
autophagy was less evident, some Beclin 1 and LC3 puncta were
detected in the CA1, CA3 and dentate gyrus of OLE-fed Tg mice
only.
To better assess the protective role of the increased autophagy
in OLE-fed mice we checked whether it results in autophagosome-
lysosome fusion. An intense cathepsin B immunoreactivity was
detected as bright puncta in small-sized lysosomes within neurons
in the superficial and deep layers of the somatosensory/parietal
and entorhinal/piriform cortices of 3.5 month-old Tg mice fed
with OLE (Fig. 5A). Significant co-localization was found in these
animals by double staining with Abs against cathepsin B and p62,
a cargo receptor targeting many cellular substrates for autophagic
degradation [44] (Fig. 5A). A similar staining was found in the wt
mice treated or untreated with OLE, independently of animal age,
as exemplified for 3.5-month-old mice (Fig. 5A), and the
quantitative analysis confirmed that cathepsin B reached similar
levels in all these mice (Fig. 5B). Altogether, these findings suggest
that the autophagosome-lysosome fusion needed for cargo
degradation is under way in OLE-fed Tg and wt mice whereas
a marked reduction of the cathepsin B expression is present in the
same cortical areas of untreated 3.5-month-old Tg mice (Fig. 5B),
with no co-localization between cathepsin B and p62, indicating a
transgene-associated dysfunction of the autophagic pathway. In
the cortex of untreated 6-month-old Tg mice (Fig. 5C), bright
cathepsin B immunoreactivity occurred mostly in enlarged
lysosomal compartments within neuronal soma (arrows) as already
reported for cathepsin D staining in the affected brain regions of 6-
month-old Tg mice [6]. As in young Tg mice fed with OLE, also
in 6-month-old Tg mice fed with OLE a bright cathepsin B
immunoreactivity appeared in small-sized lysosomes, whereas
cathepsin B-positive giant lysosomes were almost absent (Fig. 5C).
Moreover, in wt mice, either untreated or treated with OLE
(Fig. 5A), and in OLE-fed Tg mice of both ages, p62
immunoreactivity was markedly greater than in age-matched
untreated Tg mice (Fig. 5A, C), as confirmed by Western blotting
of brain extracts, here shown for 3.5-month-old mice (Fig. 5B). A
substantial lack of co-localization between cathepsin B and p62
was found in 6-month-old untreated Tg mice (Fig. 5C). As shown
for younger mice, also in this case OLE feeding was associated
with a recover of p62-cathepsin B co-localization (Fig. 5C, yellow
staining), indicating that OLE administration rescues autophago-
some-lysosome function also in advanced stages of amyloid
deposition.
OLE Increases Autophagy in N2a Cells
To confirm that autophagy in mouse brain tissue was really
induced directly by OLE, cultured N2a neuroblastoma cells were
exposed for various time periods to increasing amounts of OLE.
The time-course analysis showed that 48 h cell culturing without
medium replacement, resulting in nutrient shortage, was needed to
increase the expression of autophagic markers (Fig. 6A). However,
cells cultured similarly but exposed to 90 mM OLE displayed
increased Beclin 1 and p62 expression as compared to control cells
already after 6 h of treatment. The dose-dependence analysis
showed that LC3-II/LC3-I ratio and Beclin 1 expression increased
already after 6 h of treatment with 9.0 mM OLE; 90 mM OLE
administration resulted in a further increase of these markers
together with that of p62 (Fig. 6B). Finally, the time- and dose-
dependent decrease of phosphorylation of the mTOR substrate
p70 S6-kinase in cells exposed for 3–48 h to 50 mM OLE or for
6 h to 9.0–100 mM OLE (Fig. 6C, D) suggests that autophagy
activation by OLE proceeds through mTOR inhibition. The
Neutral Red (NR) Uptake assay, which measures cell viability in
terms of ability to retain the dye inside lysosomes, is particularly
appropriate in this context where lysosome integrity is a prominent
feature of functional autophagy activation. No significant differ-
ences in this assay were found between control and OLE-treated
cells exposed for 48 h to 90 mMOLE (OLE=99.960.9110, n= 4,
calculated with respect to control taken as 100%). These data
Figure 1. OLE restores cognitive performance in 3.5–6 month-old TgCRND8 mice. (A) Step down test: one-way ANOVA plus Bonferroni’s
post comparison test shows a statistically significant increase in the mean retention latencies in untreated and OLE-treated wt and in OLE-treated Tg
mice, as compared to their respective training latencies (1P,0.001). Untreated Tg mice do not show significant differences between training and
retention latencies (P.0.05). The retention latencies of untreated Tg mice significantly differ from the retention latencies of all the other groups
(#P,0.001). (B) ORT: in the T2 trial the discrimination index of untreated Tg mice significantly differ from the discrimination index of all other groups
(*P,0.05). The dotted line indicates the chance level performance; Data are reported as mean values 6 S.E.M. Number of animals: n = 12/group.
doi:10.1371/journal.pone.0071702.g001
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further suggest that OLE is directly responsible for autophagy
induction, is protective and does not trigger neurodegeneration
and cell death as it is the case of several polyphenols [43] and of
the prolonged treatment with rapamycin [7].
OLE Reduces Astrocyte Reaction
It is widely recognised that amyloid deposits in the brain
activate an inflammatory response that contributes to cell
sufferance and functional decline [45]. Accordingly, we investi-
gated whether OLE-treatment reduced the inflammatory response
in our Tg mice. We detected hypertrophic astrocytes with long
and thick branches in the cortex and in all the subregions of the
hippocampus of untreated Tg mice (Fig. 7 A). By contrast, in the
OLE-fed animals the astrocyte reaction was considerably milder
(Fig. 7A), indicating reduction of inflammation. The latter was not
the result of the antioxidant power of OLE; in fact, lipid
peroxidation in the cortex of 3.5-month-old Tg mice was not
significantly reduced by OLE treatment (Fig. 7C). Next, we
investigated the effect of OLE administration on microglia
morphology. Surprisingly, activated microglia with enlarged cell
bodies, thickened and retracted processes or losses of branches
were detected in the hippocampus (not shown) and cortex of OLE-
fed 6-month-old Tg mice (Fig. 7B). Such a scenario coincided and
agreed with the presence of the less dense ‘‘fluffy’’ amyloid plaques
described above, suggesting activated microglia involvement in
plaque remodelling and phagocytosis. In untreated Tg mice some
Figure 2. OLE reduces plaque burden in the cortex and hippocampus of TgCRND8 mice. (A) Representative photomicrographs of Ab42
immunopositive deposits. (n = 5/group, six sections from each mouse). Insets: high magnification images of representative plaques. Scale
bars = 500 mm applies to all reconstructed images and 20 mm to all magnified images. (B) Quantitative analysis of total plaque area and plaque
number in untreated and OLE-fed Tg mice (n = 6 for 3.5 and 6 months Tg mice). (C) ELISA: cortical levels of SDS- and formic acid-soluble Ab40 and
Ab42 peptides in OLE-fed and untreated Tg mice. Both Ab40 and Ab42 levels were significantly decreased in OLE-fed Tg versus age-matched
untreated Tg (n= 5/group) mice. *P,0.05, **P,0.01 and ***P,0.001. Data are reported as mean values 6 S.E.M. mo=month-old.
doi:10.1371/journal.pone.0071702.g002
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morphologically activated microglia were detected only in 6-
month-old animals while in 3.5-month-old mice resting microglia
with thin cell bodies and elongated branches were mostly detected
(Fig. 7B). These data support protection by OLE against the
inflammatory response to amyloid deposits mainly at the astrocyte
level, while microglia activation by OLE can mainly contribute to
plaque clearance.
Discussion
The present study provides acompelling evidence that, in
young/middle-aged TgCRND8 mice, diet supplementation for 8
weeks with OLE remarkably improves animal behavior in two
memory tests respect to normally fed littermates, with scores
reaching those displayed by age-matched wt mice. Improved
behavior is accompanied by a significant reduction in Aß40 and
Aß42 levels as well as in size and compactness of Ab plaques and
by the presence of fluffy deposits in the older Tg mice. Altogether,
our data suggest that OLE treatment reduces de novo Ab deposition
and favors preformed plaque disassembly. These results agree with
our recently reported findings on a recombinant C. elegans strain
expressing human Ab42 in the cytoplasm of muscle cells, showing
that worms grown on an OLE-supplemented medium displayed
remarkably improved motility and reduced plaque deposition
[46].
It has been already reported that the inability to acquire the step
down-inhibitory response and to explore a novel object over a
familiar one in this mouse model reflects dysfunction of cortical
areas [30,47]; Functional disruption in the neuronal network has
repeatedly been reported in AD mouse models [48]. Aberrant
neuronal activity and significant reduction of the number of active
neurons is particularly present near amyloid plaques, whose
presence causes disturbances resulting in abnormalities of whole
neuronal networks both in animal models [30,49] and in
asymptomatic patients with amyloid deposits [50]. Our data
demonstrating that OLE treatment of young/middle-aged Tg
mice results in a concomitant improvement of non-spatial episodic
memory and working memory together with amelioration of
cortical neuropathological aspects and a remarkable induction of
autophagy underscores a tight link between these effects.
TgCRND8 mice develop a pattern of Ab deposition recalling
several aspects of human AD. Small size Aß42 immunopositive
plaques appear in various brain areas, including the cortex and the
hippocampus, by the age of 3 months. As a function of age, they
become small-medium to big in size and acquire a compact core,
becoming numerous and reaching the maximum roughly by 7–8
months of age [28,30,35]. OLE administration with diet to pre-
plaque TgCRND8 mice for 8 weeks results in a remarkable
reduction of the Ab load, with a significant decrease of levels,
plaque number and area, in agreement with the in vitro anti-
aggregation effect of OLE we have reported previously [24]. In the
OLE-treated older Tg mice, the cortical levels are reduced and the
plaques appear less compact displaying ribbon-like and fluffy
morphologies in both the cortex and the hippocampus, indicating
the occurrence of dual concomitant effects of OLE, prevention of
amyloid deposition and disaggregation of preformed plaques. It is
increasingly recognised that autophagy protects neurons from Ab-
induced cytotoxicity and that autophagy dysfunction is a
molecular link between brain ageing, Ab accumulation in the
brain parenchyma and cognitive impairment [4,6,7,51]. Recently,
brain inflammation and Ab deposition following some triggering
insult have been proposed to establish a self-reinforcing cycle
integrating the amyloid cascade hypothesis presently considered at
the basis of cerebral impairment in AD [52]. Deletion of Beclin
1 in mice has been reported to increase Ab deposits, to decrease
neuronal autophagy and to promote neuronal degeneration, while
Figure 3. OLE modifies Ab plaque load and morphology in the brains of TgCRND8 mice. Representative photomicrographs of Thioflavin S
histochemistry (green) (n = 4/group) and OC immunolabeling (red) (n = 5/group) of amyloid plaques in the cortex of untreated and OLE-fed Tg mice.
In the OLE-fed Tg mice of 6 months of age several radiating plaques with ribbon-like/diffuse core and fluffy deposits (arrow) are present. Arrowhead
indicates dense core amyloid plaques. Scale bars = 25 mm.
doi:10.1371/journal.pone.0071702.g003
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gene therapy using lentivirus expressing Beclin 1 reduces amyloid
pathology in APP transgenic mice [53]. Accordingly, we associate
the amelioration of cognitive function of young/middle-aged
animals and of neuropathology with a remarkable induction of the
Figure 4. OLE increases Beclin 1 and LC3 in the cortex of wt and TgCRND8 mice. Representative images of Beclin 1 (A) and LC3 (C)
immunoreactivity showing an intense bright and punctate Beclin 1 staining in the soma, perikarya and dendrites of neurons and strong and bright
LC3 puncta in the neuronal cell bodies and processes of neurons in the somatosensory/parietal cortex of Tg mice and, to a lesser extent, in the wt
mice fed with OLE, as compared to age-matched untreated Tg and wt mice (n = 5/group). Scale bars = 50 mm applies for the low magnification
images and 20 mm applies for the high magnification images of untreated and OLE-fed 6-month-old Tg mice. (B) and (D) Western blotting analysis of
Beclin 1 (B) and LC3 (D) levels in cortical tissue, exemplified for mice of 3.5 months of age, normalized for b-actin, (n = 6–7/group). LC3 levels are
expressed as LC3-II/LC3-I levels. In the cortex of OLE-fed animals Beclin 1 levels show a trend towards an increase in the wt mice and in the OLE-fed Tg
mice Beclin 1 and LC3 levels were significantly increased respect to age-matched untreated wt and Tg mice. (**P,0.01). Data are reported as mean
values 6 S.E.M.
doi:10.1371/journal.pone.0071702.g004
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Figure 5. Autophagosome-lysosome fusion in the cortex of untreated and OLE-fed wt and Tgmice. (A) Merge of cathepsin B (green) and
p62 (red) immunoreactivity in 3.5-month-old wt and Tg mice. Co-localization between cathepsin B and p62 staining was detected as bright yellow
puncta in small-sized lysosomes in the cortex of untreated wt mice and OLE-fed Tg and wt mice (n = 6/group). Scale bar = 25 mm. Inset: high
magnification of a p62 and cathepsin B positive neuron. Scale bar = 14 mm. (B) Western blotting analysis of cathepsin B and p62 levels in the cortex of
3.5-month-old wt and Tg mice; wt =pool of untreated and OLE-fed wt mice (n = 10); Tg =untreated and OLE-fed Tg mice (N= 6/group). Both
cathepsin B and p62 levels were significantly increased in OLE-fed Tg mice, as compared to untreated Tg mice. Data are representative of four
experiments and are normalized for b-actin and reported as mean values 6 S.E.M. *P,0.05, ** P,0.01. (C) Single and double fluorescent
immunohistochemistry with cathepsin B (green) and p62 (red) Abs in the cortex of untreated and OLE-fed Tg mice. In the untreated Tg mice, bright
cathepsin B immunoreactivity occurred in enlarged lysosomal compartments (arrows), p62 immunoreactivity was light and no co-localization
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autophagic pathway in the cortex of OLE-treated Tg mice. A
strong punctuate immunoreactivity and higher levels of autopha-
gosome-lysosome markers, from Beclin-1 to LC3 and cathepsin B,
are detected in the cortex and, to a lesser extent, in hippocampal
areas of OLE-fed Tg mice at both stages of amyloid deposition, as
compared to untreated age-matched Tg mice. In the Tg mice,
OLE administration triggers the autophagic machinery to the level
detected in control wt mice and leads to the delivery of
autophagosome substrates to lysosomes for degradation, as shown
by the widespread p62-cathepsin B co-localization. By contrast, in
the untreated Tg mice autophagosome-lysosome markers analysis
reveals a clear dysfunction of the autophagic pathway. The cortical
and hippocampal astrocyte reaction detected in untreated Tg mice
is strongly ameliorated by OLE administration. This anti-
inflammatory activity of OLE treatment is not associated with
the known OLE anti-oxidant activity, which plays a minor role, if
any, in all the effects we have found. In fact, the OLE-induced
migration of microglia to the amyloid plaques favoring phagocy-
tosis of amyloid deposits could maintain/produce an oxidant
environment thus underlying the absence of significant anti-
oxidant effects of OLE administration. In addition, since OLE is
highly prone to oxidation, it probably loses its anti-oxidant power
before reaching mice brain.
Our data strongly support the idea that OLE treatment combats
Ab neurotoxicity and Ab-induced cognitive impairment in our
mouse model through reduction of plaque load and consistency
resulting from a strong induction of autophagy, concomitantly
with a recovery of the lysosomal system (whose dysfunction is one
of the earliest disturbances that occur in AD [54] and from
microglia activation. The two responses could co-operate to the
final protective effect; in fact, the migration of the activated
microglia to the Ab deposits would result in plaque disassembly
and fragmentation; the activated autophagy would complete the
protective response explaining reduced plaque burden, dimensions
and compactness The beneficial effects of the MD on attenuating
cognitive impairment, AD-like pathology and neurodegenerative
diseases has been repeatedly reported [13–18]. Overall, the
behavioral and histological data presented in our study support
the notion that the beneficial effects of the MD can, at least in part,
be traced back to the intake of EVOO and its main polyphenol,
OLE. We also provide a molecular explanation of the protective
effects elicited by OLE against age-related and AD-type neuro-
degeneration. Our findings are strengthened by previous data
indicating that in rat and humans, orally administered olive oil
phenols, including OLE, its glycoside and/or one of its derivatives
arising from tissue metabolism, are intestinally absorbed skipping
degradation by microorganisms in the colon, cross the blood-brain
barrier and are found inside brain parenchyma [55,56]. In
conclusion, our results support the possibility that dietary
supplementation of OLE may prevent or delay the occurrence
of AD and may reduce the severity of its symptoms.
between cathepsin B and p62 was found. Inset: high magnification of a cell with cathepsin B-positive giant lysosomes. In the OLE-fed Tg mice, a
bright cathepsin B immunoreactivity appeared in small-sized lysosomes, p62 immunoreactivity was greater than in untreated Tg mice and a
significant co-localization between cathepsin B and p62 was evident. (n = 6). Scale bars = 25 mm applies for single cathepsin B staining and 10 mm
applies to the inset and high magnification images.
doi:10.1371/journal.pone.0071702.g005
Figure 6. OLE activates autophagy in N2a murine neuroblastoma cells. The cells were exposed to 90 mM (A) or 50 mM (C) OLE for increasing
time periods. (B) and (D): the cells were exposed for 6 h to increasing OLE concentrations. Cells were lysed and analyzed by western blotting as
described. This is a representative experiment out of three that gave qualitatively identical results.
doi:10.1371/journal.pone.0071702.g006
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